MARKET

CLDX

CLDX

Celldex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.530
-0.030
-1.17%
After Hours: 2.490 -0.04 -1.58% 17:54 12/06 EST
OPEN
2.560
PREV CLOSE
2.560
HIGH
2.615
LOW
2.500
VOLUME
133.73K
TURNOVER
--
52 WEEK HIGH
11.62
52 WEEK LOW
2.010
MARKET CAP
40.24M
P/E (TTM)
-0.6657
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CLDX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CLDX News

  • Celldex files for $150M mixed shelf
  • seekingalpha.15h ago
  • Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159
  • GlobeNewswire.11/18 13:01
  • Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss
  • Zacks.11/14 14:44
  • UPDATE: Raymond James On Cardytics Also Notes Co's 'significant runway for key revenue drivers including MAUs and ARPU', And 'expectation for 20% plus long-term EBITDA margins'
  • Benzinga.11/13 18:24

More

Industry

Biotechnology & Medical Research
+0.66%
Pharmaceuticals & Medical Research
+0.49%

Hot Stocks

Name
Price
%Change

About CLDX

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
More

Webull offers Celldex Therapeutics, Inc. (CLDX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.